Search

Your search keyword '"Cornely, A."' showing total 179 results

Search Constraints

Start Over You searched for: Author "Cornely, A." Remove constraint Author: "Cornely, A." Publisher oxford university press / usa Remove constraint Publisher: oxford university press / usa
179 results on '"Cornely, A."'

Search Results

1. Strengthening Fungal Infection Diagnosis and Treatment: An In-depth Analysis of Capabilities in Honduras.

2. Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study.

Catalog

Books, media, physical & digital resources

5. The Nairobi Declaration 2023: A commitment to address deadly yet neglected fungal diseases in Africa.

6. Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia.

7. A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).

9. The Argentinian landscape of mycological diagnostic capacity and treatment accessibility.

10. Epidemiology, Clinical Features, and Antimicrobial Resistance of Invasive Escherichia Coli Disease in Patients Admitted in Tertiary Care Hospitals.

11. EQUAL CPA Score 2022: a tool to measure guideline adherence for chronic pulmonary aspergillosis.

12. Liposomal amphotericin B-the future.

13. Reason and reality-identifying barriers to patient enrolment for clinical trials in invasive candidiasis.

15. Invasive Trichoderma spp. infections: clinical presentation and outcome of cases from the literature and the FungiScope® registry.

16. EQUAL Trichosporon Score 2022: an ECMM score to measure QUALity of the clinical management of invasive Trichosporon infections.

17. open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.

18. current state of Clinical Mycology in Eastern and South-Eastern Europe.

19. Retrospective modelling of hospital bed capacities associated with the administration of remdesivir during the first wave of COVID-19 in a German metropolitan city.

20. EQUAL Score Scedosporiosis/Lomentosporiosis 2021: a European Confederation of Medical Mycology (ECMM) tool to quantify guideline adherence.

21. When to change treatment of acute invasive aspergillosis: an expert viewpoint.

22. Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study.

23. Development and design of the Hantavirus registry - HantaReg - for epidemiological studies, outbreaks and clinical studies on hantavirus disease.

24. Invasive infections with Purpureocillium lilacinum: clinical characteristics and outcome of 101 cases from FungiScope® and the literature.

25. Validation of the EQUAL Aspergillosis Score by analysing guideline-adherent management of invasive pulmonary aspergillosis.

26. Characterization and outcome of invasive infections due to Paecilomyces variotii: analysis of patients from the FungiScope® registry and literature reports.

27. Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium.

28. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.

29. Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial.

30. Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study.

31. Development and validation of the European QUALity (EQUAL) score for mucormycosis management in haematology.

32. Identification of Aspergillus and Mucorales in formalin-fixed, paraffin-embedded tissue samples: Comparison of specific and broad-range fungal qPCR assays.

34. Transdiaphragmatic Mucormycosis.

35. A novel approach to candidemia? The potential role of checkpoint inhibition.

36. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.

37. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.

38. Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial.

39. What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.

40. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

41. Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.

42. Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi.

43. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.

45. Perceptions of overweight in a Caribbean population: the role of health professionals.

46. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis.

47. Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

48. Domestic mould exposure and invasive aspergillosis—air sampling of Aspergillus spp. spores in homes of hematological patients, a pilot study.

49. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.

50. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.